High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells.
about
Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogenThe hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykininHeat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.Biomarkers: mining the biofluid proteome.A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.Role of Factor XII in hemostasis and thrombosis: clinical implications.Kininogens coordinate adaptive immunity through the proteolytic release of bradykinin, an endogenous danger signal driving dendritic cell maturation.The involvement of proteoglycans in the human plasma prekallikrein interaction with the cell surface.Heparan sulfate proteoglycans mediate factor XIIa binding to the cell surfaceBradykinin release avoids high molecular weight kininogen endocytosis.Defective glycosylation of coagulation factor XII underlies hereditary angioedema type IIIAssembly, activation, and physiologic influence of the plasma kallikrein/kinin system.Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.Factor XI and XII as antithrombotic targets.The procoagulant and proinflammatory plasma contact system.Kininogen-dependent antiphosphatidylethanolamine antibodies and autoantibodies to factor XII in patients with recurrent pregnancy losses.Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo.The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities.Tc-99m Glu-Cys-Gly-His-Gly-Lys (ECG-HGK), a novel Tc-99m labeled hexapeptide for molecular tumor imaging.Modulation of the Plasma Kallikrein-Kinin System Proteins Performed by Heparan Sulfate Proteoglycans.Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells.Interleukin-8 binds to syndecan-2 on human endothelial cells.Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein.Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis.Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291).Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors.The kallikrein-kinin system in experimental Chagas disease: a paradigm to investigate the impact of inflammatory edema on GPCR-mediated pathways of host cell invasion by Trypanosoma cruzi.Activation of the plasma kallikrein-kinin system on human lung epithelial cells.Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain.Transcriptional profiling identifies genes induced by hepatocyte-derived extracellular matrix in metastatic human colorectal cancer cell lines.Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides.High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib.Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells.Glycosaminoglycan Neutralization in Coagulation Control.Influence of zinc on glycosaminoglycan neutralisation during coagulation
P2860
Q24294902-F7D7BA0A-D150-4597-B40B-E53962D86253Q28216096-8AFA81E0-D87F-472B-BE81-793C448079E5Q33894624-90A69BA9-C154-48A0-AAAF-43CB795794CDQ34389937-B84FE756-FD31-4D8F-A9F9-F91FB658CE8DQ34402606-2BD21F45-5173-4D0B-A456-5FA1C5D8B48BQ34644690-D94B1D38-CDBC-4B9E-811E-31B86A35418DQ34652126-74666F04-61D5-4124-AA14-4097FC6DF400Q35118601-A969700B-E1FC-48BA-A677-A442965BB622Q35172654-CA111009-FE4F-4E4C-922D-4537CE9B913DQ35589829-88F1441E-CB30-4686-BCF4-DE9665D02303Q35700453-5054B2D0-0710-454F-A579-47D20186FBAFQ36492944-BE2EA298-678B-4A75-AB29-C4CD0F3CE917Q37315775-E12AC2AF-13E3-465F-8010-0CDD504C77C6Q37897854-86F402D3-957A-4D71-973F-9A10D49EDEA4Q37920779-AC714485-7068-4C17-9EF5-1604F7E6C83AQ38117200-8B52492D-0F08-41C9-9B77-243BA2339FDCQ38350114-2EDA50D7-3467-455B-A719-0A15322BD4ABQ38632499-6E035563-6BC5-471A-B0E0-D9879F499D2FQ38795579-DCC45C3B-0E4E-4A5E-8571-5ECFD1BDBDD1Q39458351-03C97592-F507-4573-8BF6-695C52668CF9Q40615036-2BF94D5D-B2BE-4F79-B4A0-815805E9876DQ40629075-5E6F0D64-B2F3-4767-83CA-CD6199696F64Q40762400-A0324D79-564D-4099-93F6-2F4B26CE4A1AQ41641926-86628357-4D30-425B-9992-ADEC220D053BQ41665262-06BCDB29-9EF7-4C89-8ABB-285267337552Q42134382-5102090B-3F69-491A-B34A-F4DD752D7B02Q42944340-CCC600DA-72A7-4041-8436-AEAB0264D01CQ42977921-F0B5A27F-5BE8-4366-BCB6-E17440F61503Q43035124-B55C1DC4-EEAD-45B6-80B7-AB1D267845FAQ43811222-973F0C4F-AA39-4D9F-8BB1-420061340737Q45204638-65639CD5-0F28-4402-B759-DE11F3B3F4FEQ47188768-70C4F421-2EA9-40CE-AB74-87A31AD0FCE7Q47443298-9DF69B15-6938-4B4D-94A0-305DAEDF3AF6Q52549946-3BAF935B-FC75-4173-8ED0-76F08B275373Q55086681-6BAA2485-2D15-4D41-9568-9B0E6DA87087Q58717967-45EFEE2D-B513-48E0-9112-D6E522B2DE5C
P2860
High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
High molecular weight kininoge ...... mulation on endothelial cells.
@en
type
label
High molecular weight kininoge ...... mulation on endothelial cells.
@en
prefLabel
High molecular weight kininoge ...... mulation on endothelial cells.
@en
P2093
P2860
P356
P1476
High molecular weight kininoge ...... mulation on endothelial cells.
@en
P2093
P2860
P304
33688-33696
P356
10.1074/JBC.M000313200
P407
P577
2000-10-01T00:00:00Z